Embla Medical hf.

Equities

EMBLA

IS0000000040

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe Europe Other stock markets 09:08:51 2024-04-26 am EDT			5-day change	1st Jan Change
29.8 ^DKK	+2.05%		-3.08%	+8.74%

Apr. 23	Transcript : Embla Medical hf., Q1 2024 Earnings Call, Apr 23, 2024
Apr. 23	Embla Medical hf. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Össur hf: Management changes

December 09, 2019 at 02:31 am EST

Announcement no. 74/2019
9 December 2019

New R&D leadership

Kim de Roy, EVP of Research & Development (R&D), is leaving Össur after leading the R&D function for the last 2 years.

As of today, Dr. Kristleifur Kristjansson has been appointed EVP of R&D and will become a member of Össur's Executive Management. Dr. Kristjansson joined Össur in 2012, for the first 5 years as Medical Officer and in the last 2 years as Medical Officer and VP of Clinical Affairs. Dr. Kristjansson holds a Medical Doctor degree from the University of Iceland and is a Board-Certified Pediatrician from the Medical College of Georgia, in addition to completing a clinical and molecular genetics fellowship from the Baylor College of Medicine in Houston, Texas and has been a certified Pediatrician and Clinical Geneticist in Iceland from 1993. Dr. Kristjansson's previous positions include co-founder and VP of Clinical Affairs and Collaborations at deCODE genetics ehf. 1995 to 2012 and co-founder and CEO of Pediatric Services in Iceland 1995 to 2014. Dr. Kristjansson has acted as a consulting Pediatrician and Clinical Geneticist for the University Hospital, Landspitalinn Reykjavik Iceland, from 1998 to the present, and he is the Founder and Chairman of the Board of Skraeda ehf.

Jon Sigurdsson, President & CEO, comments:

"Dr. Kristleifur Kristjansson brings with him a wealth of experience and expertise and he has been a valuable member of our team for the last 7 years. For the last 2 years Kim de Roy has been an instrumental force in driving our innovation strategy. On behalf of all Össur employees I thank him for his contribution to Össur."

Further information

David Hreidarsson, Investor Relations, dhreidarsson@ossur.com, +354 515 1380

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail please register at http://www.ossur.com/investors

About Össur

Össur (NASDAQ OMX: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of Prosthetics and Bracing & Supports. A recognized "Technology Pioneer," Össur invests significantly in research and product development-its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

https://news.cision.com/ossur-hf-/r/ossur-hf--management-changes,c2985639

https://mb.cision.com/Main/18404/2985639/1158067.pdf

Latest news about Embla Medical hf.

Transcript : Embla Medical hf., Q1 2024 Earnings Call, Apr 23, 2024	Apr. 23
Embla Medical hf. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Össur hf. will Change its Name to Embla Medical hf	Apr. 08	CI
Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee	Mar. 13	CI
Össur hf Establishes New Parent Organization to Be Named Embla Medical	Feb. 21	CI
Transcript : Össur hf., Q4 2023 Earnings Call, Jan 30, 2024	Jan. 30
Össur hf. Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 30	CI
Össur hf. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Jan. 30	CI
Össur hf. Provides Earnings Guidance for the Year 2024	Jan. 30	CI
Iceland's Össur to Purchase Fior & Gentz	Jan. 16	MT
Transcript : Fior & Gentz Gesellschaft Für Entwicklung Und Vertrieb Von Orthopädietechnischen Systemen Mbh, Össur hf. - M&A Call	Jan. 16
Össur hf. agreed to acquire Fior & Gentz Gesellschaft Für Entwicklung Und Vertrieb Von Orthopädietechnischen Systemen Mbh for ?120 million.	Jan. 15	CI
Transcript : Össur hf., Q3 2023 Earnings Call, Oct 24, 2023	23-10-24
Össur hf. Reaffirms Financial Guidance for the Year 2023	23-10-24	CI
Össur hf. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24	CI
Transcript : Össur hf., Q2 2023 Earnings Call, Jul 25, 2023	23-07-25
Össur hf. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-25	CI
Össur hf. Announces Executive Changes	23-06-15	CI
Össur hf. Provides Earnings Guidance for the Year 2023	23-04-25	CI
Transcript : Ã–ssur hf., Q1 2023 Earnings Call, Apr 25, 2023	23-04-25
Össur hf. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Össur to Seek Acquisitions	23-03-30	CI
Transcript : Össur hf. - Analyst/Investor Day	23-03-30
Transcript : Össur hf., Q4 2022 Earnings Call, Jan 31, 2023	23-01-31
Össur hf. Reports Earnings Results for the Full Year Ended December 31, 2022	23-01-31	CI

Chart Embla Medical hf.

Duration

Period

More charts

Company Profile

Embla Medical hf, formerly Ossur hf, is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The Company's business activities are divided into three business segment: The Prosthetics, its product portfolio includes a range of lower and upper limb prosthetic components; The Bracing & Supports, which offers the Unloader One range of knee braces that relieve pain from knee osteoarthritis, as well as the Unloader Hip which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip; and The Patient Care, which operates a network of Patient Care clinics around the world, with each one catering to individual patients and their needs.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-23 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Embla Medical hf.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.2 DKK

Average target price

34.52 DKK

Spread / Average Target

+18.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

	1st Jan change	Capi.
EMBLA MEDICAL HF.	+8.74%	1.79B
SONOVA HOLDING AG	-7.29%	16.43B
COCHLEAR LIMITED	+7.40%	13.63B
DEMANT A/S	+9.05%	9.89B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-19.87%	2B
ANGELALIGN TECHNOLOGY INC.	+41.47%	1.64B
MODERN DENTAL GROUP LIMITED	+13.26%	600M
ANGEL ROBOTICS CO., LTD.	0.00%	475M
DELCATH SYSTEMS, INC.	+26.44%	134M
INTEGRUM AB	+22.23%	86.89M

Medical Prosthetics